Background
Prostate cancer (PCa) is the second most common cancer type in males. It is estimated that ~1.3 million new cases and 359 000 associated deaths occurred worldwide in 2018 [1] . Radical prostatectomy and radiation therapy are effective treatment approaches for early-stage localized PCa [2] . However, ~54% of PCa patients in China present with metastasis at the time of initial diagnosis when the best treatment opportunity has already passed [3] . Bicalutamide and enzalutamide [firstand second-generation androgen receptor (AR) antagonists, respectively] initially inhibit tumor progression in the treatment of advanced PCa or castration-resistant PCa (CRPC), but their function is later limited by the development of acquired drug resistance [4] . Of note, 90% of patients who died of PCa were identified to have bone metastases on autopsy [5] .
Phospholipase C (PLC)e, a member of the PLC family, hydrolyzes membrane phosphoinositide 4,5-diphosphate to produce 2 second messengers, inositol-1,4,5-phosphate (IP3) and diacylglycerol (DAG) [6] . IP3 then stimulates Ca 2+ signaling, while DAG activates protein kinase C (PKC), which mediates a variety of biological processes, including cancer [7] . In a previous study by our group, a higher PLCe expression was determined in primary PCa (PPC) tissue compared with that in benign prostatic hyperplasia tissue, and knockdown of PLCe reduced the protein expression levels of AR [8] . However, the specific mechanism and involvement of PLCe in resistance to AR antagonists remain unclear.
Bone morphogenetic proteins (BMPs) belong to the transforming growth factor (TGF)-b superfamily. In classical BMP/SMAD signaling, BMP transduces its signals through the intracellular downstream mediator SMAD1/5/9, which forms a complex with SMAD4 after phosphorylation, regulating gene expression through cooperation with other DNA binding factors or transcription factors [9, 10] . BMP-6 has received a large amount of attention in PCa research [11] [12] [13] [14] [15] . Co-culture models of PCa/bone stromal cell lines or PCa/prostate stromal cell lines are commonly used in studies on BMP-6 [11, 12] . The WNT5A/ BMP-6 loop and BMP-6/interleukin-6 loop were reported to induce AR expression and bone metastasis in these models. However, whether BMP-6 is altered or participates in drug resistance when PCa cells are exposed to AR antagonist alone has remained elusive. In addition, a study indicated that BMP-9 was regulated via the PLC pathway by increasing intracellular levels of Ca 2+ in human periodontal ligament cells [16] . In the present study, it was hypothesized that a link exists between PLCe and BMP-6 in PCa cells.
Numerous studies have focused on AR antagonist resistance, but most of them were performed shortly after the drug was applied to PCa cells, which is not in accordance with the timing of the rise of resistance in clinical practice. To investigate the mechanisms activated following long-term treatment, LNCaP cells were cultured with bicalutamide or enzalutamide for more than 6 months to obtain drug-resistant cell lines. In the present study, BMP-6 was identified as differentially expressed in acquired drug resistance through a bioinformatics analysis of a gene array dataset, and the association between PLCe and BMP-6 was explored at the cellular level and in clinical specimens. Overall, the present results suggest that PLCe promotes cell proliferation and invasion by modulating the BMP6/SMAD axis, and PLCe knockdown increases the sensitivity of drug-resistant cells to AR antagonist, which may therefore be a potential treatment for CRPC.
Material and Methods
Identification of differentially expressed genes (DEGs) and pathways in acquired drug resistance through online database screening
To identify genes involved in the process of acquired drug resistance, the Gene Expression Omnibus (GEO) database (http:// www.ncbi.nlm.nih.gov/geo/) was searched and the GSE78201 dataset was selected [17] . The gene expression in this dataset was then analyzed using the online tool GEO2R (https:// www.ncbi.nlm.nih.gov/geo/geo2r/). Genes that met the criteria P<0.05 and log 2 |fold change| >1.5 were defined as DEGs. Gene ontology (GO) enrichment analysis and signaling pathway analysis were then performed using WebGestalt (http:// www.webgestalt.org/option.php).
Cell culture, treatment, and transfection
The LNCaP cell line was obtained from the American Type Culture Collection (Manassas, VA, USA). As previously described [18] , LNCaP cells were continuously cultured with 10 µM bicalutamide or enzalutamide (Selleck Chemicals, Houston, TX, USA). Initially, the cells died in large numbers, and the surviving cells continued to undergo passaging. After 6 months of culture, cells resistant to bicalutamide or enzalutamide (referred to as LNCaP-Bica R and LNCaP-Enza R cells, respectively) were obtained. All cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) (both from Gibco-Life Technologies, Carlsbad, CA, USA) and 1% penicillin/streptomycin (Beyotime Institute of Biotechnology) and culture of the drug-resistant cells was continued in the presence of the corresponding drugs at the above concentrations.
To study the pathways by which PLCe regulates BMP-6, 10 nM phorbol 12-myristate 13-acetate (PMA; Abcam, Cambridge, UK, USA) was added to the drug-resistant cells with PLCe knockdown, followed by culture for 24 h. Lentivirus (LV) expressing small hairpin (sh) RNA targeting human PLCe (LV-shPLCe; sequence, 5'-GGTTCTCTCCTAGAAGCAACC-3') and negative control (LV-NC; sequence, 5'-TTCTCCGAACGTGTCACGT-3') were purchased from Shanghai Gene Pharma Corp. (Shanghai, China). In brief, for transfection, LNCaP-Bica R and LNCaP-Enza R cells were seeded in 6-well plates, and when cells reached 60-70% confluence, they were transfected with 15 µl LV-shPLCe or LV-NC stock solution with 2 µl polybrene, followed by incubation at 37°C for 48 h. Stably transfected cells were selected using medium containing puromycin (1 µg/ml).
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
Total RNA was isolated from cells using TRIzol reagent following the manufacturer's protocol and stored at -80°C. RT was performed using the Prime Script™ RT reagent kit (Takara Bio, Inc., Otsu, Japan). The comparative 2 -DDCq method [19] was used for calculating the gene expression, which was normalized against b-actin. 
Western blot analysis
In brief, cells were lysed with radioimmunoprecipitation assay buffer containing phenylmethane sulfonyl fluoride and phosphatase inhibitors (NaF and Na 3 VO 4 ). The protein concentration was determined using the BCA Protein Assay kit (Beyotime Institute of Biotechnology), and 30 μg of proteins from each sample were loaded. Proteins were separated by SDS-PAGE, transferred to polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA), incubated with primary antibodies overnight at 4°C and secondary antibodies for 2 h at room temperature, and, finally, protein bands were visualized using an enhanced chemiluminescence kit (Merck Millipore, Billerica, MA, USA). The antibodies were as follows: PLCe (1: 300 dilution; cat. no. sc28402; Santa Cruz Biotechnology, Dallas, TX, USA), BMP-6 (1: 1,000 dilution; cat. no. ab155963), ID2 (1: 1,000 dilution; cat. no. ab166708) and b-actin (1: 3,000 dilution; cat. no. ab8226) were from Abcam (Cambridge, MA, USA), SMAD1/5/9 (1: 500 dilution; cat. no. 131100) and AR (1: 500 dilution; cat. no. GTX29474) were from GeneTex (San Antonio, TX, USA), phosphorylated (p)-SMAD1/5/9 (cat. no. 13820T), E-cadherin (cat. no. 3195), N-cadherin (cat. no. 4061) and matrix metallopeptidase (MMP9) (cat. no. 3852) were from Cell Signaling Technology (Danvers, MA, USA; 1: 1,000 dilution), goat anti-mouse IgG (cat. no. SA00001-1) and goat anti-rabbit IgG (cat. no. SA00001-2) were obtained from ProteinTech (Chicago, IL, USA; 1: 3,000 dilution).
MTT assay
For the cell viability assays, 2×10 3 cells were seeded into each well of a 96-well plate, followed by incubation overnight and subsequent treatment with 10 μM bicalutamide or enzalutamide, with or without 10 ng/ml human recombinant (r) BMP-6 (R&D Systems, Minneapolis, MN, USA) over 4 days, with the proliferation assessed once per day in designated wells. MTT was added, followed by incubation for 4 h at 37°C. Subsequently, the medium was discarded and 150 ml dimethyl sulfoxide was added per well. The absorbance was measured on a microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA) at 490 nm.
For determining the half-maximal inhibitory concentration (IC 50 ), various concentrations of bicalutamide or enzalutamide were added, and for the LV-shPLCe+rBMP-6 group, 10 ng/ml rBMP-6 was additionally added. The absorbance was measured after 48 h of treatment.
Colony formation assay and Transwell assay
All cells were treated with AR antagonist, with or without 10 ng/ml rBMP-6, and incubated for 3 days. A total of 500 cells per well were seeded in 6-well plates and cultured for 10 days to form colonies. For the Transwell assay, 1.0×10 4 cells were seeded in the upper chamber of the insert coated with Matrigel for 48 h, as described previously [20] .
Patients and tissue samples
A total of 48 PPC and 33 CRPC samples were collected from the Department of Urology at the First Affiliated Hospital of Chongqing Medical University (Chongqing, China) between July 2012 and June 2018. The patients with CRPC were diagnosed according to the EAU-ESTRO-SIOG guidelines [21] . All patients with CRPC had received bicalutamide (n=25) or flutamide (n=8). Bone metastasis was identified by bone scan. The present study was approved by the Ethics Committee of Chongqing Medical University (Chongqing, China) and all patients provided written informed consent.
Immunohistochemical analysis
All tissue samples were fixed in 10% neutral formalin, embedded in paraffin, and cut into 5-µm-thick sections.
Immunohistochemical staining was performed using a standard immunoperoxidase staining procedure. Semi-quantitative analysis was performed to analyze the immunohistochemical results. Scoring for the immunoreactivity ratio was as follows: 0, 0%; 1, <5%; 2, 5-50%; and 3, >50%. Scoring for intensity was performed as follows: 0, no staining; 1, light yellow; 2, light brown; and 3, brown. The 2 scores were added together to obtain the final immunoreactivity scores, and samples with scores of £2 were considered as having no expression, while those with scores of ³3 were considered to be positive [22] .
Statistical analysis
Statistical analyses were performed using SPSS software version 21.0 and GraphPad Prism software ver. 5. The significant differences among experimental groups were evaluated using the t test, one-way analysis of variance (ANOVA), and two-way ANOVA, while Bonferroni's adjustment was made for multiple comparisons. The Kaplan-Meier method was used for survival analysis. Continuous and categorical data were analyzed by Spearman's correlation analysis, chi-square test, Mann-Whitney test, and the Student-Newman-Keuls test. P<0.05 was considered to indicate a statistically significant difference. All experiments were performed at least 3 times.
Results

Online database screening for DEGs
The dataset GSE78201 was retrieved from the GEO database and analyzed. Comparisons were made between LNCaP and LNCaP-Enza R cells (Table 1) . Volcano plots were drawn to visualize the distribution of the DEGs, with green or red dots representing significantly downregulated or upregulated genes, respectively ( Figure 1A ). A total of 206 DEGs were identified (Table 2) . GO biological process analysis indicated that these genes are mainly involved in biological regulation and metabolic processes. In the GO category 'cellular component', terms enriched by the DEGs were associated with membranes and vesicles. Enriched terms in the GO category 'molecular function' mainly indicated involvement in protein binding, ion binding, and nucleic acid binding ( Figure 1B) . Pathway enrichment analysis suggested that these DEGs mainly participate in the regulation of drug metabolism, transcriptional dysregulation in cancer, and in the TGF-b signaling pathway ( Figure 1C) . As an important member of the TGF-b family, BMP-6 signaling was identified as the focus of subsequent in vitro research. Figure 2B ), suggesting that drug-resistant cells were successfully generated. RTq-PCR verified that BMP-6 and ID2 mRNA was consistently upregulated, and BMP-6, p-SMAD1/5/9 and ID2 proteins were increased in LNCaP-Bica R and LNCaP-Enza R cells, while SMAD1/5/9 was unchanged ( Figure 2C, 2D) . In conclusion, AR antagonist treatment activated BMP-6/SMAD signaling in CRPC cell lines.
BMP-6/SMAD signaling is activated in LNCaP-
BMP-6 is induced by PLCe through activation of PKC in drug-resistant cells
To verify the previous hypothesis that BMP-6 is induced by PLCe, the mRNA and protein levels of PLCe were first assessed using RT-qPCR and Western blot analysis. The results indicated that the mRNA and protein levels of PLCe were upregulated in drug-resistant cells ( Figure 2C, 2E LNCaP-Bica R and LNCaP-Enza R cells was then performed using lentivirus. Compared with those in the negative controls (Blank and LV-NC), the mRNA levels of PLCe and BMP-6 were downregulated ( Figure 2F, 2G) , and similar results were obtained at the protein level ( Figure 2H ). To further elucidate the mechanisms through which PLCe mediates BMP-6 expression, PKC activator (PMA) was added to the PLCe knockdown group. The result indicated that PMA treatment increased BMP-6 at the mRNA ( Figure 2I ) and protein levels ( Figure 2J ) in LNCaP-Bica R and LNCaP-Enza R cells, suggesting that PLCe increases BMP-6 expression at the transcriptional level in a PKC-dependent manner. (I, J) PMA (10 nM) was added to drug-resistant cells with PLCe knockdown, followed by culturing for 24 h. BMP-6 mRNA and protein levels were measured using RT-qPCR and Western blot analysis, respectively, with b-actin serving as the control. * P<0.05; ** P<0.01; *** P<0.001. RT-qPCR -reverse transcription-quantitative polymerase chain reaction; PLC -phospholipase C; BMP -bone morphogenetic protein; NC -negative control; LV-shPLCe -lentivirus expressing small hairpin RNA targeting PLCe; IC 50 -drug concentration causing 50% cell inhibition; PMA -phorbol 12-myristate 13-acetate. 
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PLCe knockdown inhibits cellular drug resistance, proliferation, and invasion via BMP-6/SMAD signaling An MTT assay indicated that the viability of cells was markedly inhibited in a time-dependent manner after transfection with LV-shPLCe ( Figure 3A, 3B) . At the same time, rBMP-6 replenishment in the LV-shPLCe group partly recovered the suppressive effect produced by PLCe knockdown. As presented in Figure 3C , the protein levels of p-SMAD1/5/9, ID2 and AR were significantly downregulated following knockdown of PLCe, and when rBMP-6 was added to PLCe-knockdown cells, these proteins were partially upregulated. In addition, the IC 50 of bicalutamide in the LNCaP-Bica R -shPLCe cells dropped to one-third of that in LNCaPBica R cells, which was partially reversed when cultured with Figure 3D ). Similar changes were observed in LNCaP-Enza R cells with the same treatment ( Figure 3E ), indicating that PLCe promoted PCa cell resistance to AR antagonist via BMP-6 signaling.
Previous studies reported that BMP-6 is associated with bone metastasis [15] . To investigate whether this process is regulated by PLCe, epithelial-to-mesenchymal transition (EMT)-associated molecules were detected by Western blot analysis following different treatments. PLCe knockdown resulted in an increased protein expression of E-cadherin and had a suppressive effect on N-cadherin and MMP9 expression, while the opposite effect was observed with the addition of rBMP-6 ( Figure 3F ). The size of the resistant cells was different and showed a multi-polar morphology under a microscope. After knocking down PLCe, the cell morphology became round and the cluster growth was more obvious. After treatment with rBMP-6, the cell morphology became long and fusiform, and migratory capacity was enhanced ( Figure 3G ). Consistent with this, a Transwell assay demonstrated that the invasive ability was significantly decreased by PLCe knockdown and was increased by rBMP-6 ( Figure 3H, 3J) . Furthermore, a colony formation assay confirmed that PLCe inhibited the proliferation of cells by regulating BMP-6 ( Figure 3I, 3K ).
Taken together, these results suggest that PLCe knockdown partially restored the sensitivity of CRPC cells to AR antagonist and simultaneously inhibited cell proliferation and invasion via BMP-6/SMAD signaling.
PLCe and BMP-6 are correlated with bone metastasis and shorter time to progression (TTP)
As the in vitro research suggested that PLCe promotes cell proliferation and invasion via the BMP-6/SMAD axis, the expression of PLCe and BMP-6 in PPC and CRPC tissue specimens was then verified by immunohistochemistry and their association with the demographic and clinical characteristics of the subjects was determined ( Figure 4A ). The results demonstrated that PLCe and BMP-6 were upregulated in CRPC compared Figure 4D ). Regarding the clinical characteristics, PLCe and BMP-6 expression were associated with bone metastasis (P<0.05; Table 3 Figure 4F ]. In summary, the expression of PLCe and BMP-6 predicted a poor prognosis for patients with PCa.
Discussion
CRPC is an important challenge in the treatment of PCa, and bone metastasis also seriously affects the quality of life of patients. Although comprehensive research has been performed to explore the mechanisms of drug resistance arising during AR antagonist treatment, the molecular mechanisms are complex and remain to be fully elucidated. In the present study, the GEO database was screened for genes and pathways that may potentially be involved in resistance to AR antagonists. Subsequently, bicalutamide-and enzalutamide-resistant cells were generated and cultured to accurately simulate the clinical occurrence of drug resistance in patients. These drug-resistant cells may be valuable models for studying CRPC. Finally, the molecular mechanisms were explored in the cells in vitro and in clinical specimens, and a potential therapeutic target for CRPC was thereby identified.
According to previous studies, PLCe is associated with numerous cancer types. It is an oncogene in cancer types including head and neck cancer, bladder cancer, and PCa, but functions as a tumor suppressor gene in colorectal cancer [23] . This difference may be partly caused by the complex structure of PLCe and the multiple signaling pathways involved. A previous study by our group demonstrated that PLCe promoted the proliferation of PCa cells [24] . The present study indicated that PLCe knockdown suppressed the proliferation and invasion of LNCaP-Bica R and LNCaP-Enza R cells, suggesting the promoting effect of PLCe in CRPC.
Due to the low expression of BMP-6 in PCa cell lines [25] , most studies of BMP-6 use PCa/bone stromal or PCa/prostate stromal cell line co-culture models. It was also reported that PLCe promotes the expression of BMP-9 by increasing the intracellular levels of Ca 2+ in periodontal ligament cells [16] , while another study revealed that BMP-2 and BMP-4 were regulated by PKC in human osteosarcoma cell lines [26] . While PLCe regulates various different downstream molecules and signaling pathways, the present study indicated that PLCe may regulate BMP-6 expression by activating PKC. To the best of our knowledge, the present study is the first to report that BMP-6 is regulated by the PLCe/PKC pathway in drug-resistant PCa cell lines, providing a novel therapeutic approach via modification of BMP-6 expression.
There are certain controversies regarding the effect of BMP-6 on the proliferation of PCa cell lines. A study by Haudenschild et al. [27] demonstrated that BMP-6 inhibited the proliferation of DU145 and LNCaP cells, but Lee et al. [11] reported that cell proliferation was enhanced when LNCaP cells were cultured with BMP-6 in androgen-depleted media. Another study observed no marked effect of BMP-6 on the proliferation of LuCaP 23.1 or C4-2B cells [15] . Thus, in different cell lines, different BMP-6 concentrations and culture conditions may lead to different results. Studies by our and other groups [11, 28] support that BMP-6 promotes cell proliferation with a parallel increase of p-SMAD, confirming the importance of the BMP-6/SMAD axis in tumor progression.
A previous study indicated that p-SMAD5 interacts with b-catenin to induce AR expression in PCa cells [11] . A previous study by our group also suggested that b-catenin is activated in LNCaP-Bica R and LNCaP-Enza R cells. In the present study, PLCe knockdown suppressed BMP-6/p-SMAD1/5/9 and AR expression. Combined with the results of the above study, it may be inferred that PLCe-induced drug resistance is due to overexpression of AR caused by the BMP6/p-SMAD signaling pathway. The present study also indicated that downregulation of PLCe inhibited BMP-6/SMAD/ID2 signaling and expression of the EMT-associated molecules E-cadherin, N-cadherin, and MMP9, reducing the invasive behavior of drug-resistant cells. EMT is a recognized key process for tumor invasion and metastasis [29] . In line with the present results, previous studies have indicated that, as a molecule downstream of BMP/ SMAD, ID2 induces EMT-associated factors and enhances the aggressiveness of cancers [30] [31] [32] . Immunohistochemical analysis suggested that PLCe and BMP-6 proteins were upregulated in CRPC, which were associated with bone metastasis and a shorter TTP. However, further studies with larger numbers of patients and matched PPC and CRPC tissues from the same patient are required.
Other pathways have been identified to be associated with drug resistance through bioinformatics analyses, including steroid hormone biosynthesis and cytochrome P450-linked drug metabolism, which we will further examine in a future study. Overall, the present results indicate that the BMP-6/ SMAD pathway was activated by PLCe in drug-resistant cells; PLCe knockdown partially restored the sensitivity of CRPC cells to AR antagonists and inhibited the malignant behavior of cells. Therefore, PLCe/BMP-6 may have a critical role in monitoring of CRPC progression and targeted therapy.
Conclusions
Our study has shown that PLCe knockdown partially restored the sensitivity of CRPC cells to AR antagonists through the BMP-6/SMAD pathway as well as inhibiting the malignant behavior of cells. Thus, these findings may provide a new approach for treating CRPC.
